Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Hong Wu)

Study leads

Jason Wu
Study Chair
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Philadelphia, United States